JP5792316B2 - Ｃｈｋ１を阻害するのに有用な化合物 - Google Patents
Ｃｈｋ１を阻害するのに有用な化合物 Download PDFInfo
- Publication number
- JP5792316B2 JP5792316B2 JP2013537756A JP2013537756A JP5792316B2 JP 5792316 B2 JP5792316 B2 JP 5792316B2 JP 2013537756 A JP2013537756 A JP 2013537756A JP 2013537756 A JP2013537756 A JP 2013537756A JP 5792316 B2 JP5792316 B2 JP 5792316B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- methoxy
- pyridin
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41113710P | 2010-11-08 | 2010-11-08 | |
| US61/411,137 | 2010-11-08 | ||
| PCT/US2011/058692 WO2012064548A1 (en) | 2010-11-08 | 2011-11-01 | Compounds useful for inhibiting chk1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541586A JP2013541586A (ja) | 2013-11-14 |
| JP2013541586A5 JP2013541586A5 (https=) | 2014-12-18 |
| JP5792316B2 true JP5792316B2 (ja) | 2015-10-07 |
Family
ID=45044707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537756A Active JP5792316B2 (ja) | 2010-11-08 | 2011-11-01 | Ｃｈｋ１を阻害するのに有用な化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9067920B2 (https=) |
| EP (1) | EP2638033B1 (https=) |
| JP (1) | JP5792316B2 (https=) |
| KR (1) | KR101533166B1 (https=) |
| CN (1) | CN103180311B (https=) |
| AR (1) | AR083575A1 (https=) |
| AU (1) | AU2011326230B2 (https=) |
| BR (1) | BR112013010009B1 (https=) |
| CA (1) | CA2816944C (https=) |
| DK (1) | DK2638033T3 (https=) |
| EA (1) | EA022096B1 (https=) |
| ES (1) | ES2541414T3 (https=) |
| HR (1) | HRP20150530T1 (https=) |
| JO (1) | JO3145B1 (https=) |
| ME (1) | ME02119B (https=) |
| MX (1) | MX2013005181A (https=) |
| PL (1) | PL2638033T3 (https=) |
| PT (1) | PT2638033E (https=) |
| RS (1) | RS54012B1 (https=) |
| SI (1) | SI2638033T1 (https=) |
| TW (1) | TWI501956B (https=) |
| WO (1) | WO2012064548A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| HRP20220351T1 (hr) | 2016-02-04 | 2022-05-13 | Pharmaengine, Inc. | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| AU2021389190A1 (en) | 2020-11-30 | 2023-06-29 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1h-pyrazol-3-amine derivative |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| US20250129049A1 (en) * | 2021-12-24 | 2025-04-24 | Sumitomo Pharma Co., Ltd. | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| US20250352541A1 (en) * | 2022-05-27 | 2025-11-20 | Sumitomo Pharma Co., Ltd. | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| TW202442234A (zh) * | 2023-04-14 | 2024-11-01 | 美商纜圖藥品公司 | Ｃｄｋ２抑制劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06000933A (es) * | 2003-07-25 | 2006-03-30 | Pfizer | Compuestos de aminopirazol y uso como inhibidores de chk1. |
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| CN101218229A (zh) * | 2005-05-05 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用 |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
-
2011
- 2011-10-27 JO JOP/2011/0323A patent/JO3145B1/ar active
- 2011-10-27 AR ARP110103973A patent/AR083575A1/es active IP Right Grant
- 2011-10-28 TW TW100139492A patent/TWI501956B/zh active
- 2011-11-01 EA EA201390499A patent/EA022096B1/ru not_active IP Right Cessation
- 2011-11-01 WO PCT/US2011/058692 patent/WO2012064548A1/en not_active Ceased
- 2011-11-01 AU AU2011326230A patent/AU2011326230B2/en active Active
- 2011-11-01 SI SI201130467T patent/SI2638033T1/sl unknown
- 2011-11-01 US US13/877,923 patent/US9067920B2/en active Active
- 2011-11-01 KR KR1020137011808A patent/KR101533166B1/ko active Active
- 2011-11-01 JP JP2013537756A patent/JP5792316B2/ja active Active
- 2011-11-01 CA CA2816944A patent/CA2816944C/en active Active
- 2011-11-01 EP EP11788263.9A patent/EP2638033B1/en active Active
- 2011-11-01 DK DK11788263T patent/DK2638033T3/en active
- 2011-11-01 RS RS20150352A patent/RS54012B1/sr unknown
- 2011-11-01 BR BR112013010009-5A patent/BR112013010009B1/pt active IP Right Grant
- 2011-11-01 ME MEP-2015-69A patent/ME02119B/me unknown
- 2011-11-01 HR HRP20150530TT patent/HRP20150530T1/hr unknown
- 2011-11-01 MX MX2013005181A patent/MX2013005181A/es active IP Right Grant
- 2011-11-01 CN CN201180053779.8A patent/CN103180311B/zh active Active
- 2011-11-01 PT PT117882639T patent/PT2638033E/pt unknown
- 2011-11-01 PL PL11788263T patent/PL2638033T3/pl unknown
- 2011-11-01 ES ES11788263.9T patent/ES2541414T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011326230A1 (en) | 2013-05-09 |
| EP2638033A1 (en) | 2013-09-18 |
| EA201390499A1 (ru) | 2013-08-30 |
| CA2816944C (en) | 2015-12-22 |
| KR101533166B1 (ko) | 2015-07-01 |
| BR112013010009B1 (pt) | 2021-10-19 |
| CN103180311A (zh) | 2013-06-26 |
| DK2638033T3 (en) | 2015-04-27 |
| BR112013010009A2 (pt) | 2020-09-29 |
| PT2638033E (pt) | 2015-06-01 |
| JO3145B1 (ar) | 2017-09-20 |
| EP2638033B1 (en) | 2015-04-08 |
| CA2816944A1 (en) | 2012-05-18 |
| TWI501956B (zh) | 2015-10-01 |
| AR083575A1 (es) | 2013-03-06 |
| CN103180311B (zh) | 2014-08-20 |
| JP2013541586A (ja) | 2013-11-14 |
| ME02119B (me) | 2015-10-20 |
| US20130190262A1 (en) | 2013-07-25 |
| HRP20150530T1 (hr) | 2015-06-19 |
| US9067920B2 (en) | 2015-06-30 |
| WO2012064548A1 (en) | 2012-05-18 |
| EA022096B1 (ru) | 2015-10-30 |
| RS54012B1 (sr) | 2015-10-30 |
| PL2638033T3 (pl) | 2015-09-30 |
| ES2541414T3 (es) | 2015-07-20 |
| KR20130099146A (ko) | 2013-09-05 |
| SI2638033T1 (sl) | 2015-05-29 |
| AU2011326230B2 (en) | 2015-02-19 |
| TW201305138A (zh) | 2013-02-01 |
| MX2013005181A (es) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5792316B2 (ja) | Ｃｈｋ１を阻害するのに有用な化合物 | |
| CN113614083B (zh) | 咪唑酮基喹啉化合物及其治疗用途 | |
| JP6169185B2 (ja) | キナーゼ阻害剤としての新規ベンゾイミダゾール誘導体 | |
| KR101718645B1 (ko) | Cdc7 억제제 | |
| BR112015014752B1 (pt) | Compostos e seus uso para modulação de cinase | |
| JP2012512249A (ja) | Ｃｈｋ１を阻害するために有用な化合物 | |
| EP3706735A1 (en) | Pim kinase inhibitor compositions, methods, and uses thereof | |
| CN114222747A (zh) | Pim激酶抑制剂组合物及其用途 | |
| JP6752878B2 (ja) | 神経芽細胞腫及び／または軟部組織肉腫の処置における使用のためのｃｈｋ１／２阻害剤 | |
| CN117229264A (zh) | 一类含有2-氨基嘧啶结构的芳基席夫碱类化合物及其应用 | |
| RU2822479C2 (ru) | Соединения имидазолонилхинолина и их терапевтическое применение | |
| WO2025160079A1 (en) | Indazolo-amino-pyrimidinone compounds | |
| WO2024040241A1 (en) | Pharmaceutical formulations, processes for preparation, and methods of use | |
| FR2969607A1 (fr) | Nouveaux derives de thiopyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141030 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141030 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150709 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150805 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5792316 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |